LON:PRTC PureTech Health (PRTC) Share Price, News & Analysis GBX 131.20 +3.60 (+2.82%) As of 06/12/2026 12:22 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock About PureTech Health Stock (LON:PRTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PureTech Health alerts:Sign Up Key Stats Today's Range 128.60▼ 13550-Day Range 113▼ 139.2052-Week Range 104.71▼ 148Volume756,520 shsAverage Volume1.19 million shsMarket Capitalization£319.36 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 508Consensus RatingBuy Company Overview PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts. Read More PureTech Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScorePRTC MarketRank™: PureTech Health scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPureTech Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialPureTech Health has a consensus price target of GBX 508, representing about 287.2% upside from its current price of GBX 131.20.Amount of Analyst CoveragePureTech Health has received no research coverage in the past 90 days.Read more about PureTech Health's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PureTech Health is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PureTech Health is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPureTech Health has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PRTC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPureTech Health does not currently pay a dividend.Dividend GrowthPureTech Health does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.30 News SentimentPureTech Health has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PureTech Health this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for PRTC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added PureTech Health to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PureTech Health insiders have not sold or bought any company stock.Percentage Held by Insiders13.35% of the stock of PureTech Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions34.02% of the stock of PureTech Health is held by institutions.Read more about PureTech Health's insider trading history. Receive PRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTC Stock News HeadlinesPureTech Health Wins Full Shareholder Backing at 2026 AGMJune 10, 2026 | tipranks.comPureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC)June 9, 2026 | uk.finance.yahoo.comSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $1.75 trillion valuation and 266 times earnings, you're buying in at the most expensive IPO in history - right when institutions who got in at $800 billion need someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure Colossus can't run without - and it's still trading at a fraction of its value.June 14 at 1:00 AM | Behind the Markets (Ad)PureTech Health PLC Sponsored ADRMay 14, 2026 | edition.cnn.comPureTech’s Seaport Therapeutics Prices Enlarged $254.9 Million Nasdaq IPOMay 1, 2026 | uk.finance.yahoo.comPureTech to Exit Nasdaq Listing and Consolidise Trading in LondonApril 29, 2026 | uk.finance.yahoo.comPureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy VolunteersApril 2, 2026 | uk.finance.yahoo.comPureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug ...March 25, 2026 | finance.yahoo.comSee More Headlines PRTC Stock Analysis - Frequently Asked Questions How have PRTC shares performed this year? PureTech Health's stock was trading at GBX 125 at the beginning of 2026. Since then, PRTC stock has increased by 5.0% and is now trading at GBX 131.20. How do I buy shares of PureTech Health? Shares of PRTC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of PureTech Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that PureTech Health investors own include IQE (IQE), BP (BP), GSK (GSK), Hummingbird Resources (HUM), Plug Power (PLUG) and AstraZeneca (AZN). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:PRTC CIKN/A Webpuretechhealth.com Phone+1-617-4822333FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Price Target for PureTech HealthGBX 508 High Price TargetGBX 508 Low Price TargetGBX 508 Potential Upside/Downside+287.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX (46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£91.86 million Net Margins-2,355.32% Pretax MarginN/A Return on Equity-31.98% Return on Assets-13.39% Debt Debt-to-Equity Ratio6.33 Current Ratio6.59 Quick Ratio2.51 Sales & Book Value Annual Sales£4.66 million Price / Sales68.55 Cash FlowGBX 61.26 per share Price / Cash Flow2.14 Book ValueGBX 113.55 per share Price / Book1.16Miscellaneous Outstanding Shares243,418,000Free FloatN/AMarket Cap£319.36 million OptionableNot Optionable Beta0.81 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (LON:PRTC) was last updated on 6/14/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredThe number nobody's bragging aboutSPCX - the largest IPO in history - was predicted to open at $175. It opened at $150. Insiders bought in at a ...Behind the Markets | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredThere’s a new type of capitalismThe U.S. government has taken direct equity positions in at least 10 companies - Intel, U.S. Steel, Westinghou...Porter & Company | SponsoredBUY THIS: Claim a backdoor stake in SpaceXThere may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Share PureTech Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
